MEMORANDUM FOR SGOIC
ATTN: LT COL STEVEN J. ACEVEDO

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled Regulation of EGF and Prostaglandin Expression During Neonatal Gastrointestinal Injury in a Non-Human Primate Explant Model presented at/published to Pediatric Academic Societies Meeting, San Francisco CA, 5-9 May 2017 in accordance with MDWI 41-108, has been approved and assigned local file #17199.

2. Pertinent biographic information (name of author(s) title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist’s Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support
1. The author must complete page two of this form:  
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (BG5 O&M); BG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.)  
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.  

2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.  

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, information report/briefing, etc.) in the "Protocol Title" box.  

4. Attach a copy of your abstract, paper, poster and other supporting documentation.  

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.  

6. On page 2, have either your unit commander, program director or immediate supervisor:  
   a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.  

7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubsres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7144 for assistance.  

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.  

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.  

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-108, Publication and Publication of Medical and Technical Papers, for additional information.  

11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honors, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:  

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.  

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.  

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.  

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.  

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.  

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.  

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:  
"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"  

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:  
"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."  

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:  
"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
Induction of EGF by PG2 as a Protective Mechanism of Intestinal Barrier Function and Cell Survivability in FHsInt74 Cell Line

Regulation of EGF and Prostaglandin Expression During Neonatal Gastrointestinal Injury in a Non-Human Primate Explant Model

Funding received for this study: YES
Funding source: Air Force Research Grant

DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES

IS THIS MATERIAL CLASSIFIED?: NO

MATERIAL IS FOR: DOMESTIC RELEASE

CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.

PUBLICATION/JOURNAL (List intended publication/journal.)

PUBLISHED ABSTRACT (List intended journal.)

POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)
Pediatric Academic Societies Meeting, San Francisco, CA, May 5-9

PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)

OTHER (Describe: name of meeting, city, state, and date of meeting.)

HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?
YES

EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC

DATE
April 17, 2017

59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
Acevedo, Steven J
210-916-7078

AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.

LAST NAME, FIRST NAME AND M.I.  GRADE/RANK  SQUADRON/GROUP/OFFICE SYMBOL  INSTITUTION (If not 59 MDW)

Acevedo, Steven J  O5/Lt Col  959 CSPS/SGOIC  Trinity University

King, Johnathan  Civ  

Carr, Nicholas  O4/Maj  959 MDOS/SGOIC  UT Health San Antonio

Blanco, Cynthia  Civ  

Mustafa, Shamim  Civ  

CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401-IP, AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

DATE
March 17, 2017
### 1st ENDORSEMENT

**TO:** Clinical Research Division  
59 MDW/CRD  
Contact 252-7141 for email instructions.

**DATE RECEIVED:** 4/12/2017  
**ASSIGNED PROCESSING REQUEST FILE NUMBER:** 17199

**DATE REVIEWED:** April 25, 2017

**AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES:** ☒ NO ☐ YES If yes, give date. ☐ N/A

**COMMENTS:** ☒ APPROVED ☐ DISAPPROVED

---

### 2nd ENDORSEMENT (602 IS/IG/JAC Use Only)

**DATE RECEIVED**

---

### 3rd ENDORSEMENT (68 MDW/PA Use Only)

**DATE RECEIVED:** April 25, 2017  
**DATE FORWARDED TO 59 MDW/PA:**

---

### 4th ENDORSEMENT (68 MDW/SGVU Use Only)

**DATE RECEIVED**

---

**METHODOLOGY**

Approved as a abstract presentation, not a poster since no poster is attached.

---

**SIGNATURES**

**REVIEWER:** ANNEKE C. BUSH, DAF, GS-14, Clinical Research Administrator  
**REVIEWER SIGNATURE:**

---

**SIGNATURES**

**REVIEWER:** Kevin Inuma, SSgt/E-5, 59 MDW Public Affairs  
**REVIEWER SIGNATURE:**

---

**SIGNATURES**

**REVIEWER:**

---

---
TITLE: Regulation of EGF and Prostaglandin Expression During Neonatal Gastrointestinal Injury in a Non-Human Primate Explant Model

AUTHORS: Steven J. Acevedo, MD1, Nicholas B. Alana2, Nicholas R. Carr, DO1, Cynthia L. Blanco MD3, Shamim B. Mustafa PhD3, Jonathan M. King PhD2

ADDRESS: 1Department of Neonatology, San Antonio Military Medical Center, San Antonio, Texas 2Department of Biology, Trinity University, San Antonio, Texas 3Department of Pediatrics/Division of Neonatology, University of Texas Health Science Center, San Antonio, Texas

BACKGROUND: Alterations in the Epidermal Growth Factor (EGF) and/or function of the EGF receptor (EGFR), have been related to GI injury. Bioactive compounds like Prostaglandin E2 (PGE2) also appear to have a role in barrier maintenance. A model evaluating the interaction of such compounds in vivo does not exist.

OBJECTIVE: Develop an ex vivo model to evaluate alterations/interactions of several bioactive compounds within the same tissue exposed to anti-inflammatory (indomethacin) and inflammatory (TNF) modulators.

DESIGN/METHODS: Preterm baboons delivered at 125-day gestation (term=184 days) via C-section were sacrificed at birth (D0=125 day, n=5) or chronically ventilated for 14 days (D14=125day + 14days, n=5). Explants were harvested from proximal ileum, cecum, and colon. Tissue was cultured for 24 hours while exposed to an inflammatory agent (TNF 10 ng/ml), or anti-inflammatory agent (indomethacin 50 mM). Secreted PGE2 in culture media was quantified by ELISA. mRNA expression of prostanoid (EP) receptor subtypes, EGFR, AKT, and inducible nitric oxide synthase (iNOS) were evaluated by qRT-PCR. Protein isolates were measured by ELISA for EGFR, p-EGFR, and AKT.

RESULTS: PGE2 secretion was similar between D0 and D14 controls. PGE2 secretion varied across intestinal regions significantly in control groups (p<0.05), pronounced in the terminal ileum. A reduction in PGE2 secretion was noted in D0 and D14 tissues exposed to indomethacin alone or with TNF in all three intestinal regions (p<0.05). There was a 2 to 4-fold downregulation in mRNA expression of EP2/EP4/EGFR/AKT and inducible NO in D0 tissue, exposed to either TNF or indomethacin in the ileum (p<0.05). These changes were not significant in D14 ileum with exception of iNOS elevation in indomethacin exposed tissues (p<0.05). Protein expression was modestly affected by age of tissue or changes in gene expression. TNF did not change PGE2 secretion, but downregulated gene expression and protein content in the EGFR pathway.

CONCLUSIONS: An explant model efficiently replicates in vivo tissue behavior allowing for testing of confounding variables within the same tissue and translation to an in vivo model. Indomethacin suppressed PGE2 secretion in preterm tissue and reduced gene expression in the EGFR pathway as a potential pathway for irreparable GI injury.

The views expressed are those of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.

The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended.